Houlihan Lokey Advises TriMed

Houlihan Lokey is pleased to announce that TriMed, Inc., has sold a majority interest to Henry Schein, Inc.

Headquartered in Santa Clarita, California, TriMed is a leader in developing creative and clinically relevant surgical solutions that improve treatment in both the upper and lower extremities. In 2022, TriMed had net sales of approximately $48 million.

Henry Schein, the world’s largest provider of healthcare solutions to office-based dental and medical practitioners, announced it will acquire a majority interest in TriMed, a global developer of solutions for the orthopedic treatment of lower extremities (foot and ankle) and upper extremities (primarily hand and wrist). With approximately 24,000 Team Schein Members worldwide, the company’s network of trusted advisors provides more than 1 million customers globally with over 300 valued solutions that help improve operational success and clinical outcomes. Henry Schein operates through a centralized and automated distribution network, with a selection of more than 300,000 branded products and Henry Schein private-brand products in stock.

This transaction further strengthens and highlights Houlihan Lokey’s continued leadership in the medical technology industry. Houlihan Lokey’s Healthcare Group is among the largest dedicated healthcare investment banking groups in the world. In 2022, the group closed 37 transactions and was ranked by Refinitiv as the No. 1 advisor for U.S. and global healthcare M&A transactions under $1 billion.*

Houlihan Lokey served as the exclusive financial advisor to TriMed and assisted in initiating, structuring, and negotiating the transaction on its behalf.

*Excludes accounting firms and brokers.